Issue 221

Welcome back to E&O: SaMD, a paying subscribers-only weekly newsletter focused on the world of digital pharma products, prescription digital therapeutics and other FDA-regulated digital health.

 E&O: Software as a Medical Device

Here's a quick rundown of things happening in FDA-regulated and pharma-focused digital health:

• Akili shared its Q4 results with investors this week. The company had 11,571 active paying EndeavorOTC users